# **DFV Deutsche Familienversicherung AG Germany - Financial Services**



Buy (old: Buy)

Price target: EUR 30.00 (old: EUR 30.00)

Price: EUR 19.91 **Next result:** Q4/FY 20 tba **Bloomberg:** DFVA GR Market cap: EUR 261.1 m Reuters: DFV.DE **Enterprise Value:** EUR 246.9 m 13-November-20

**Christian Salis** Analyst

christian.salis@ha-ib.de Tel.: +49 40 414 3885 96

# Shift towards digital continues to fuel strong growth in Q3

DFV published solid Q3 results reflecting that the company is well protected against COVID-19 thanks to its digitized insurance platform.

GWP rose by 25% yoy to € 29.8m (eH&A: € 29.7m) in Q3 showing significant growth driven by the structural shift towards digital, as well as rising brand awareness thanks to successful marketing initiatives. Following an initial dip due to COVID-19, dental insurance (50% of total contracts) has shown a solid rebound while pet insurance continued to thrive (eH&A: +3k gog contracts in Q3). Meanwhile, travel insurance (15% of total contracts) continued to be burdened by muted travel activity. As a result, the number of new contracts came in at 21k in Q3 below the FY'20 run-rate of 100k. More importantly, existing premiums rose to € 120m as of 9M-20 putting DFV fully on track to achieve its FY'20 target of € 125m.

Q3 EBIT improved to € -1.0m versus € -1.7m in Q3'19 (adjusted for € 3m positive one-offs), showing the scalability of the business model despite investments to prepare for CareFlexChemie in 2021, including recruiting 55 employees for IT, admin and customer service as well as IT investments (i.e. server expansion). With that, EBIT arrived at € -7m in 9M'20, putting DFV well on track to achieve its **FY'20 target** of € -9m to € -11m EBIT (eH&A: € -10.8m, eCons: € -10m).

DFV should also be well on track to execute on its mid-term ambition of 1.1m contracts in 2021E and a premium volume of at least € 200m supported by the CareFlex Chemie deal which looks set to double DFV's client base by July 2021. In the mid-term, DFV looks set to achieve 2m contracts, € 500m premium volume and a 10% EBIT margin driven by economies of scale thanks to its lean and fully digitized insurtech setup.

Meanwhile, the stock is still trading at an 80% discount to US peer Lemonade (USD/contract: USD 600 vs USD 3,260) which looks unjustified, in our view. In fact, while Lemonade Lemonade grows faster (120% yoy vs 27% yoy in 9M'20 for DFV), DFV shows much better profitability (net income € -4.7m vs USD -75m in 9M).

BUY, PT € 30.00, based on DCF.

			2018	2019	2020E	2021E	2022E
Sales	64.1	70.7	66.5	90.9	116.0	183.9	264.2
Sales growth	1 %	10 %	-6 %	37 %	28 %	59 %	44 %
EBITDA	3.5	3.7	-1.1	-2.2	-8.3	13.8	25.1
EBIT	2.0	2.1	-4.1	-5.2	-10.8	10.8	21.4
Net income	1.7	1.5	-3.3	-2.0	-7.5	7.6	15.1
Net debt	-4.7	-5.5	-9.0	-3.7	-30.2	-36.6	-48.5
Net gearing	-25.2 %	-28.3 %	-14.8 %	-5.8 %	-39.0 %	-51.0 %	-68.7 %
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	0.13	0.10	-0.25	-0.15	-0.51	0.52	1.03
CPS	1.06	1.07	0.40	0.97	0.23	0.72	1.12
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend yield	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Gross profit margin	44.4 %	44.7 %	54.2 %	59.8 %	60.0 %	60.8 %	61.3 %
EBITDA margin	5.5 %	5.2 %	-1.7 %	-1.6 %	-7.1 %	7.5 %	9.5 %
EBIT margin	3.2 %	3.0 %	-6.2 %	-3.8 %	-9.3 %	5.9 %	8.1 %
ROCE	4.1 %	3.5 %	-4.4 %	-4.0 %	-7.7 %	7.0 %	12.3 %
EV/sales	3.9	3.8	3.6	1.8	2.1	1.3	0.9
EV/EBITDA	70.0	73.5	-213.1	-114.0	-29.8	17.6	9.2
EV/EBIT	122.6	128.2	-58.8	-48.4	-22.9	22.3	10.8
PER	139.8	176.3	-71.5	-116.8	-34.8	34.2	17.4
Adjusted FCF yield	1.2 %	0.9 %	-1.0 %	-0.4 %	-5.4 %	7.4 %	17.0 %

Source: Company data, Hauck & Aufhäuser Close price as of: 12.11.2020



Source: Company data, Hauck & Aufhäuser

High/low 52 weeks: 26.50 / 9.99

38

Price/Book Ratio: Relative performance (-): 3 months 6 months 12 months

# Changes in estimates

		Sales	EBIT	EPS
2020	old:	116.0	-10.8	-0.51
2020	Δ	-	-	-
2021	old:	183.9	10.8	0.52
2021	Δ	-	-	-
2022	old:	264.2	21.4	1.03
2022	Δ	-	-	-

## Kev share data:

Number of shares: (in m pcs) 13.9 Authorised capital: (in € m) Book value per share: (in €) 5.3 Ø trading volume: (12 months) 13,500

# Major shareholders:

Free Float	26.1 %
Luca Pesarini	21.1 %
Dr. Stefan Knoll (CEO)	19.5 %
Vogel Family & Heir	19.1 %
VPV Versicherungen	14.3 %

## Company description:

The DFV is an early mover in the insurtech field being the first fully digital insurance company in Europe and among the healthiest worldwide.

# **Financials**

Profit and loss (EUR m)	2016	2017	2018	2019	2020E	2021E	2022E
Sales	64.1	70.7	66.5	90.9	116.0	183.9	264.2
Sales growth	1.4 %	10.3 %	-5.9 %	36.7 %	27.6 %	58.5 %	43.7 %
Cost of sales	35.6	39.1	30.4	36.6	46.4	72.1	102.3
Gross profit	28.4	31.6	36.1	54.4	69.6	111.8	162.0
Sales and marketing	-0.4	1.5	-1.3	4.0	2.3	5.5	7.9
General and administration	16.8	18.0	20.2	33.0	43.3	65.3	92.0
Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	7.9	11.4	14.5	25.4	32.5	34.0	47.3
Other operating expenses	1.4	1.6	4.1	5.2	7.0	7.2	9.2
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	3.5	3.7	-1.1	-2.2	-8.3	13.8	25.1
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITA	3.5	3.7	-1.1	-2.2	-8.3	13.8	25.1
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.5	1.6	3.0	3.0	2.5	2.9	3.7
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	2.0	2.1	-4.1	-5.2	-10.8	10.8	21.4
Interest income	0.0	0.0	0.0	0.0	0.1	0.1	0.1
Interest expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	0.0	0.0	0.0	0.0	0.1	0.1	0.1
Recurring pretax income from continuing operations	2.0	2.1	-4.1	-5.2	-10.7	10.9	21.5
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	2.0	2.1	-4.1	-5.2	-10.7	10.9	21.5
Taxes	0.3	0.6	-0.8	-3.1	-3.2	3.3	6.5
Net income from continuing operations	1.7	1.5	-3.3	-2.0	-7.5	7.6	15.1
Result from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	1.7	1.5	-3.3	-2.0	-7.5	7.6	15.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit (reported)	1.7	1.5	-3.3	-2.0	-7.5	7.6	15.1
Average number of shares	13.3	13.9	13.3	13.3	13.9	14.6	14.6
EPS reported	0.13	0.11	-0.25	-0.15	-0.54	0.52	1.03

Cost of sales       55.6 %       55.3 %       4         Gross profit       44.4 %       44.7 %       9         Sales and marketing       neg.       2.2 %         General and administration       26.2 %       25.5 %       3         Research and development       0.0 %       0.0 %       0.0 %         Other operating income       12.3 %       16.2 %       2         Unusual or infrequent items       0.0 %       0.0 %       0.0 %         EBITDA       5.5 %       5.2 %         Depreciation       0.0 %       0.0 %       0.0 %         EBITA       5.5 %       5.2 %         Amortisation of goodwill       0.0 %       0.0 %       0.0 %         Amortisation of intangible assets       2.4 %       2.2 %         Impairment charges       0.0 %       0.0 %         EBIT (inc revaluation net)       3.2 %       3.0 %         Interest income       0.0 %       0.0 %         Interest expenses       0.0 %       0.0 %         Other financial result       0.0 %       0.0 %         Financial result       0.0 %       0.0 %	30.4 % 36.2 0.0 % 0.0 % 21.9 % 27.9 6.2 % 5.7 0.0 % 0.0 <b>neg. n</b> 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %	2 % 40.0 % 60.0 % 4 % 2.0 % 37.3 % 0.0 % 0.0 % 9 % 28.0 % 7 % 6.0 % 0.0 % eg. 0.0 % eg. 0.0 % eg. 0.0 % 0.0 % eg. 0.0 % 0.0 % eg. 0.0 % 3 % 2.2 %	39.2 % 60.8 % 3.0 % 35.5 % 0.0 % 18.5 % 3.9 % 0.0 % 7.5 % 0.0 % 7.5 %	100.0 % 38.7 % 61.3 % 3.0 % 34.8 % 0.0 % 17.9 % 3.5 % 0.0 % 9.5 % 0.0 % 9.4 %
Gross profit         44.4 %         44.7 %         9           Sales and marketing         neg.         2.2 %           General and administration         26.2 %         25.5 %         3           Research and development         0.0 %         0.0 %         0.0 %           Other operating income         12.3 %         16.2 %         2           Unusual or infrequent items         0.0 %         0.0 %           EBITDA         5.5 %         5.2 %           Depreciation         0.0 %         0.0 %           EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	54.2 % 59.8 neg. 4.4 36.2 0.0 % 0.0 21.9 % 27.9 6.2 % 5.7 0.0 % 0.0 neg. n 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0	8 % 60.0 % 4 % 2.0 % 2 % 37.3 % 0 % 0.0 % 9 % 28.0 % 7 % 6.0 % 0 % 0.0 % eg. neg. 0 % 0.0 % leg. neg. 0 % 0.0 %	60.8 % 3.0 % 35.5 % 0.0 % 18.5 % 3.9 % 0.0 % 7.5 % 0.0 % 7.5 % 0.0 %	61.3 % 3.0 % 34.8 % 0.0 % 17.9 % 3.5 % 0.0 % 9.5 % 0.0 % 9.5 % 0.0 %
Sales and marketing         neg.         2.2 %           General and administration         26.2 %         25.5 %         3           Research and development         0.0 %         0.0 %         0.0 %           Other operating income         12.3 %         16.2 %         2           Unusual or infrequent items         0.0 %         0.0 %         0.0 %           EBITDA         5.5 %         5.2 %         5.2 %           Depreciation         0.0 %         0.0 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	neg. 4.4 30.4 % 36.2 0.0 % 0.0 21.9 % 27.9 6.2 % 5.7 0.0 % 0.0 neg. n 0.0 % 0.0 neg. n 0.0 % 0.0 4.5 % 3.3	4 % 2.0 % 2 % 37.3 % 0 % 0.0 % 9 % 28.0 % 7 % 6.0 % 0 % 0.0 % eg. neg. 0 % 0.0 % leg. neg. 0 % 0.0 % 3 % 2.2 %	3.0 % 35.5 % 0.0 % 18.5 % 3.9 % 0.0 % 7.5 % 0.0 % 7.5 % 0.0 %	3.0 % 34.8 % 0.0 % 17.9 % 3.5 % 0.0 % 9.5 % 0.0 % 9.5 % 0.0 %
General and administration       26.2 %       25.5 %       3         Research and development       0.0 %       0.0 %       0.0 %         Other operating income       12.3 %       16.2 %       2         Other operating expenses       2.1 %       2.2 %       2         Unusual or infrequent items       0.0 %       0.0 %       0.0 %         EBITDA       5.5 %       5.2 %       5.2 %         Depreciation       0.0 %       0.0 %       5.2 %         Amortisation of goodwill       0.0 %       0.0 %       0.0 %         Amortisation of intangible assets       2.4 %       2.2 %       1         Impairment charges       0.0 %       0.0 %       0.0 %         EBIT (inc revaluation net)       3.2 %       3.0 %         Interest income       0.0 %       0.0 %       0.0 %         Other financial result       0.0 %       0.0 %       0.0 %         Financial result       0.0 %       0.0 %       0.0 %	30.4 % 36.2 0.0 % 0.0 % 21.9 % 27.9 6.2 % 5.7 0.0 % 0.0 <b>neg. n</b> 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %	2 % 37.3 % 0.0 % 0.0 % 9 % 28.0 % 6.0 % 0.0 % eg. neg. 0 % 0.0 % leg. neg. 0 % 0.0 % 3 % 2.2 %	35.5 % 0.0 % 18.5 % 3.9 % 0.0 % 7.5 % 0.0 % 7.5 % 0.0 %	34.8 % 0.0 % 17.9 % 3.5 % 0.0 % 9.5 % 0.0 % 9.5 % 0.0 %
Research and development         0.0 %         0.0 %           Other operating income         12.3 %         16.2 %         2           Other operating expenses         2.1 %         2.2 %           Unusual or infrequent items         0.0 %         0.0 %           EBITDA         5.5 %         5.2 %           Depreciation         0.0 %         0.0 %           EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	0.0 % 0.0 21.9 % 27.5 6.2 % 5.7 0.0 % 0.0 <b>neg. n</b> 0.0 % 0.0 <b>neg. n</b> 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0	0 % 0.0 % 9 % 28.0 % 7 % 6.0 % 0 % 0.0 % leg. neg. 0 % 0.0 % leg. neg. 0 % 0.0 % 3 % 2.2 %	0.0 % 18.5 % 3.9 % 0.0 % 7.5 % 0.0 % 7.5 % 0.0 %	0.0 % 17.9 % 3.5 % 0.0 % 9.5 % 0.0 % 9.5 % 0.0 %
Other operating income         12.3 %         16.2 %         2           Other operating expenses         2.1 %         2.2 %           Unusual or infrequent items         0.0 %         0.0 %           EBITDA         5.5 %         5.2 %           Depreciation         0.0 %         0.0 %           EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	21.9 % 27.5 6.2 % 5.7 0.0 % 0.0 <b>neg. n</b> 0.0 % 0.0 <b>neg. n</b> 0.0 % 0.0 4.5 % 3.3	9 % 28.0 % 7 % 6.0 % 0 % 0.0 % leg. neg. 0 % 0.0 % leg. neg. 0 % 0.0 %	18.5 % 3.9 % 0.0 % 7.5 % 0.0 % 7.5 % 0.0 %	17.9 % 3.5 % 0.0 % 9.5 % 0.0 % 9.5 % 0.0 %
Other operating expenses       2.1 %       2.2 %         Unusual or infrequent items       0.0 %       0.0 %         EBITDA       5.5 %       5.2 %         Depreciation       0.0 %       0.0 %         EBITA       5.5 %       5.2 %         Amortisation of goodwill       0.0 %       0.0 %         Amortisation of intangible assets       2.4 %       2.2 %         Impairment charges       0.0 %       0.0 %         EBIT (inc revaluation net)       3.2 %       3.0 %         Interest income       0.0 %       0.0 %         Interest expenses       0.0 %       0.0 %         Other financial result       0.0 %       0.0 %         Financial result       0.0 %       0.0 %	6.2 % 5.7 0.0 % 0.0 neg. n 0.0 % 0.0 neg. n 0.0 % 0.0 4.5 % 3.3	7 % 6.0 % 0.0 % eg. neg. 0 % 0.0 % neg. neg. 0 % 0.0 % 3 % 2.2 %	3.9 % 0.0 % <b>7.5 %</b> 0.0 % <b>7.5 %</b> 0.0 %	3.5 % 0.0 % <b>9.5 %</b> 0.0 % <b>9.5 %</b> 0.0 %
Unusual or infrequent items         0.0 %         0.0 %           EBITDA         5.5 %         5.2 %           Depreciation         0.0 %         0.0 %           EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	0.0 % 0.0 neg. n 0.0 % 0.0 % 0.0 4.5 % 3.3	0 % 0.0 % neg. 0 % 0.0 % neg. neg. 0 % 0.0 % 3 % 2.2 %	0.0 % 7.5 % 0.0 % 7.5 % 0.0 %	0.0 % <b>9.5 %</b> 0.0 % <b>9.5 %</b> 0.0 %
EBITDA         5.5 %         5.2 %           Depreciation         0.0 %         0.0 %           EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	neg.         n           0.0 %         0.0           neg.         n           0.0 %         0.0           4.5 %         3.3	neg. neg. 0 % 0.0 % neg. neg. 0 % 0.0 % 3 % 2.2 %	7.5 % 0.0 % 7.5 % 0.0 %	9.5 % 0.0 % 9.5 % 0.0 %
Depreciation         0.0 %         0.0 %           EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	0.0 % 0.0 neg. n 0.0 % 0.0 4.5 % 3.3	0 % 0.0 % <b>neg. neg.</b> 0 % 0.0 % 3 % 2.2 %	0.0 % <b>7.5 %</b> 0.0 %	0.0 % <b>9.5 %</b> 0.0 %
EBITA         5.5 %         5.2 %           Amortisation of goodwill         0.0 %         0.0 %           Amortisation of intangible assets         2.4 %         2.2 %           Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	neg.         n           0.0 %         0.0           4.5 %         3.3	neg. neg. 0 % 0.0 % 3 % 2.2 %	<b>7.5 %</b> 0.0 %	<b>9.5 %</b> 0.0 %
Amortisation of goodwill       0.0 %       0.0 %         Amortisation of intangible assets       2.4 %       2.2 %         Impairment charges       0.0 %       0.0 %         EBIT (inc revaluation net)       3.2 %       3.0 %         Interest income       0.0 %       0.0 %         Interest expenses       0.0 %       0.0 %         Other financial result       0.0 %       0.0 %         Financial result       0.0 %       0.0 %	0.0 % 0.0 4.5 % 3.3	0 % 0.0 % 3 % 2.2 %	0.0 %	0.0 %
Amortisation of intangible assets       2.4 %       2.2 %         Impairment charges       0.0 %       0.0 %         EBIT (inc revaluation net)       3.2 %       3.0 %         Interest income       0.0 %       0.0 %         Interest expenses       0.0 %       0.0 %         Other financial result       0.0 %       0.0 %         Financial result       0.0 %       0.0 %	4.5 % 3.3	3 % 2.2 %		
Impairment charges         0.0 %         0.0 %           EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %			1.6 %	14%
EBIT (inc revaluation net)         3.2 %         3.0 %           Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	0.0%			/0
Interest income         0.0 %         0.0 %           Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	0.0 /0 0.0	0.0 %	0.0 %	0.0 %
Interest expenses         0.0 %         0.0 %           Other financial result         0.0 %         0.0 %           Financial result         0.0 %         0.0 %	neg. n	ieg. neg.	5.9 %	8.1 %
Other financial result 0.0 % 0.0 % Financial result 0.0 % 0.0 %	0.0 % 0.0	0 % 0.1 %	0.0 %	0.0 %
Financial result 0.0 % 0.0 %	0.0 % 0.0	0.0 %	0.0 %	0.0 %
	0.0 % 0.0	0.0 %	0.0 %	0.0 %
	0.0 % 0.0	0 % 0.1 %	0.0 %	0.0 %
Recurring pretax income from continuing operations 3.2 % 3.0 %	neg. n	ieg. neg.	5.9 %	8.1 %
Extraordinary income/loss 0.0 % 0.0 %	0.0 % 0.0	0.0 %	0.0 %	0.0 %
Earnings before taxes 3.2 % 3.0 %	neg. n	ieg. neg.	5.9 %	8.1 %
Tax rate 16.0 % 30.1 %	18.7 % 60.6	6 % 30.0 %	30.0 %	30.0 %
Net income from continuing operations 2.7 % 2.1 %	neg. n	ieg. neg.	4.2 %	5.7 %
Result from discontinued operations (net of tax) 0.0 % 0.0 %	0.0 % 0.0	0.0 %	0.0 %	0.0 %
Net income 2.7 % 2.1 %	neg. n	ieg. neg.	4.2 %	5.7 %
Minority interest 0.0 % 0.0 %	0.0 % 0.0	0.0 %	0.0 %	0.0 %
Net profit (reported) 2.7 % 2.1 %	neg. n	ieg. neg.	4.2 %	5.7 %

Balance sheet (EUR m)	2016	2017	2018	2019	2020E	2021E	2022E
Intangible assets	9.6	9.3	9.2	8.7	9.5	10.5	11.5
Property, plant and equipment	2.1	1.4	1.4	1.4	1.4	1.4	1.4
Financial assets	31.7	46.4	90.1	121.7	121.7	127.8	134.2
FIXED ASSETS	43.4	57.1	100.6	131.8	132.7	139.7	147.1
Inventories	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable	3.4	1.9	4.9	5.3	5.3	5.0	7.1
Other current assets	20.7	29.4	35.0	40.5	46.0	52.7	60.4
Liquid assets	4.7	5.5	9.0	3.7	30.2	36.6	48.5
Deferred taxes	0.5	0.4	2.0	5.9	5.9	5.9	5.9
Deferred charges and prepaid expenses	0.0	0.0	5.1	2.8	2.8	2.8	2.8
CURRENT ASSETS	29.2	37.2	56.0	58.1	90.1	102.9	124.7
TOTAL ASSETS	72.6	94.3	156.7	189.8	222.8	242.6	271.8
SHAREHOLDERS EQUITY	18.5	19.5	60.7	64.3	77.4	71.7	70.6
MINORITY INTEREST	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-term debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	15.1	15.9	12.8	16.0	16.0	17.6	19.4
Other provisions	20.9	31.4	44.3	58.0	68.2	80.5	95.2
Non-current liabilities	36.1	47.3	57.1	74.0	84.2	98.1	114.6
short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	16.8	26.0	37.9	48.2	57.9	69.5	83.4
Deferred taxes	1.3	1.5	1.0	3.3	3.3	3.3	3.3
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	18.0	27.5	38.8	51.5	61.2	72.8	86.6
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	72.6	94.3	156.7	189.9	222.8	242.6	271.8

Balance sheet (common size)	2016	2017	2018	2019	2020E	2021E	2022E
Intangible assets	13.2 %	9.9 %	5.9 %	4.6 %	4.3 %	4.3 %	4.2 %
Property, plant and equipment	2.9 %	1.5 %	0.9 %	0.7 %	0.6 %	0.6 %	0.5 %
Financial assets	43.7 %	49.2 %	57.5 %	64.1 %	54.6 %	52.7 %	49.4 %
FIXED ASSETS	59.8 %	60.5 %	64.2 %	69.4 %	59.5 %	57.6 %	54.1 %
Inventories	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Accounts receivable	4.7 %	2.0 %	3.1 %	2.8 %	2.4 %	2.0 %	2.6 %
Other current assets	28.4 %	31.2 %	22.3 %	21.3 %	20.7 %	21.7 %	22.2 %
Liquid assets	6.4 %	5.8 %	5.7 %	1.9 %	13.6 %	15.1 %	17.8 %
Deferred taxes	0.6 %	0.4 %	1.3 %	3.1 %	2.6 %	2.4 %	2.2 %
Deferred charges and prepaid expenses	0.0 %	0.0 %	3.2 %	1.5 %	1.2 %	1.1 %	1.0 %
CURRENT ASSETS	40.2 %	39.5 %	35.8 %	30.6 %	40.4 %	42.4 %	45.9 %
TOTAL ASSETS	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
SHAREHOLDERS EQUITY	25.5 %	20.6 %	38.8 %	33.9 %	34.7 %	29.6 %	26.0 %
MINORITY INTEREST	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Long-term debt	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Provisions for pensions and similar obligations	20.8 %	16.8 %	8.2 %	8.4 %	7.2 %	7.3 %	7.1 %
Other provisions	28.8 %	33.3 %	28.3 %	30.6 %	30.6 %	33.2 %	35.0 %
Non-current liabilities	49.7 %	50.2 %	36.5 %	39.0 %	37.8 %	40.4 %	42.2 %
short-term liabilities to banks	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Accounts payable	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Advance payments received on orders	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Other liabilities (incl. from lease and rental contracts)	23.1 %	27.6 %	24.2 %	25.4 %	26.0 %	28.6 %	30.7 %
Deferred taxes	1.8 %	1.6 %	0.6 %	1.7 %	1.5 %	1.4 %	1.2 %
Deferred income	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Current liabilities	24.8 %	29.2 %	24.8 %	27.1 %	27.5 %	30.0 %	31.9 %
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %

Cash flow statement (EUR m)	2016	2017	2018	2019	2020E	2021E	2022E
Net profit/loss	1.7	1.5	-3.3	-2.0	-7.5	7.6	15.1
Depreciation of fixed assets (incl. leases)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.5	1.6	3.0	3.0	2.5	2.9	3.7
Others	2.3	2.8	9.9	13.7	10.0	1.6	1.8
Cash flow from operations before changes in w/c	5.6	5.9	9.6	14.6	5.0	12.2	20.5
Increase/decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in accounts receivable	9.2	10.8	-3.0	-0.3	0.0	0.3	-2.2
Increase/decrease in accounts payable	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in working capital	9.2	10.8	-3.0	-0.3	0.0	0.3	-2.2
Cash flow from operating activities	14.8	16.6	6.6	14.3	5.0	12.5	18.3
CAPEX	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	17.0	14.8	48.7	25.0	10.0	6.1	6.4
Income from asset disposals	-1.7	-1.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	-18.7	-15.8	-48.7	-25.0	-10.0	-6.1	-6.4
Cash flow before financing	-3.9	0.9	-42.1	-10.7	-5.0	6.4	12.0
Increase/decrease in debt position	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	45.6	6.1	31.5	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	0.0	0.0	-0.7	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	0.0	0.0	45.6	5.4	31.5	0.0	0.0
Increase/decrease in liquid assets	-3.9	0.9	3.5	-5.3	26.5	6.4	12.0
Liquid assets at end of period	4.7	5.5	9.0	3.7	30.2	36.6	48.5

Source: Company data, Hauck & Aufhäuser

Regional split (EUR m)	2016	2017	2018	2019	2020E	2021E	2022E
Domestic	64.1	70.7	66.5	90.9	116.0	183.9	264.2
yoy change	1.4 %	10.3 %	-5.9 %	36.7 %	27.6 %	58.5 %	43.7 %
Rest of Europe	0.0	0.0	0.0	0.0	0.0	0.0	0.0
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NAFTA	0.0	0.0	0.0	0.0	0.0	0.0	0.0
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Asia Pacific	0.0	0.0	0.0	0.0	0.0	0.0	0.0
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Rest of world	0.0	0.0	0.0	0.0	0.0	0.0	0.0
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TTL	64.1	70.7	66.5	90.9	116.0	183.9	264.2
yoy change	1.4 %	10.3 %	-5.9 %	36.7 %	27.6 %	58.5 %	43.7 %

Key ratios (EUR m)	2016	2017	2018	2019	2020E	2021E	2022E
P&L growth analysis							
Sales growth	1.4 %	10.3 %	-5.9 %	36.7 %	27.6 %	58.5 %	43.7 %
EBITDA growth	82.3 %	4.3 %	-130.7 %	93.5 %	632.3 %	-729.7 %	-402.8 %
EBIT growth	185.8 %	4.8 %	-293.7 %	25.8 %	162.9 %	-310.2 %	-298.4 %
EPS growth	95.7 %	-16.9 %	-335.3 %	-38.8 %	115.4 %	-441.9 %	-291.3 %
Efficiency							
Total operating costs / sales	41.2 %	41.7 %	60.4 %	65.5 %	69.3 %	54.9 %	53.2 %
Sales per employee	481.8	593.7	583.3	821.8	1,032.9	1,589.4	2,217.5
EBITDA per employee	26.6	31.0	-9.9	-19.8	-73.8	119.2	210.7
Balance sheet analysis							
Avg. working capital / sales	7.7 %	3.8 %	5.1 %	5.6 %	4.4 %	2.8 %	2.3 %
Inventory turnover (sales/inventory)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Trade debtors in days of sales	19.4	9.8	9.8	9.8	9.8	9.8	9.8
A/P turnover [(A/P*365)/sales]	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash conversion cycle (days)	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cash flow analysis							
Free cash flow	14.8	16.6	6.6	14.3	5.0	12.5	18.3
Free cash flow/sales	23.1 %	23.5 %	9.9 %	10.6 %	4.3 %	6.8 %	6.9 %
FCF / net profit	870.1 %	1122.1 %	neg.	neg.	neg.	163.3 %	121.9 %
Capex / depn	1118.1 %	937.6 %	1638.6 %	841.6 %	400.0 %	206.9 %	172.8 %
Capex / maintenance capex	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / sales	26.5 %	20.9 %	73.2 %	27.5 %	8.6 %	3.3 %	2.4 %
Security							
Net debt	-4.7	-5.5	-9.0	-3.7	-30.2	-36.6	-48.5
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net debt / equity	neg.	neg.	neg.	neg.	neg.	neg.	neg.
Interest cover	999.0	999.0	999.0	999.0	999.0	999.0	999.0
Dividend payout ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Asset utilisation							
Capital employed turnover	1.2	1.1	0.6	0.7	0.7	1.1	1.4
Operating assets turnover	11.6	21.5	10.6	13.7	17.5	29.0	31.1
Plant turnover	30.5	51.3	48.3	66.0	84.3	133.6	192.0
Inventory turnover (sales/inventory)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Returns							
ROCE	4.1 %	3.5 %	-4.4 %	-4.0 %	-7.7 %	7.0 %	12.3 %
ROE	9.2 %	7.6 %	-5.5 %	-3.2 %	-9.7 %	10.7 %	21.3 %
Other							
Interest paid / avg. debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a
No. employees (average)	133	119	114	111	112	116	119
Number of shares	13.3	13.9	13.3	13.3	13.9	14.6	14.6
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	0.13	0.11	-0.25	-0.15	-0.54	0.52	1.03
Valuation ratios							
P/BV	12.8	13.4	3.9	3.7	3.4	3.6	3.7
EV/sales	3.9	3.8	3.6	1.8	2.1	1.3	0.9
EV/EBITDA	70.0	73.5	-213.1	-114.0	-29.8	17.6	9.2
EV/EBITA	70.0	73.5	-213.1	-114.0	-29.8	17.6	9.2
EV/EBIT	122.6	128.2	-58.8	-48.4	-22.9	22.3	10.8
EV/FCF	16.8	16.3	36.7	17.4	49.5	19.4	12.6
Adjusted FCF yield	1.2 %	0.9 %	-1.0 %	-0.4 %	-5.4 %	7.4 %	17.0 %
Adjusted i Ci yield	1.2 /0	0.5 70	-1.0 /0	-0.4 /6	-3.4 /0	7.4 /0	17.0 %

Disclosures regarding research publications of Hauck & Aufhäuser Privatbankiers AG pursuant to section 85 of the German Securities Trading Act (WpHG) and distributed in the UK under an EEA branch passport, subject to the FCA requirements on research recommendation disclosures

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. Further to this, under the FCA's rules on research recommendations, any conflicts of interest in connection with the recommendation must be disclosed. A conflict of interest is presumed to exist in particular if Hauck & Aufhäuser Privatbankiers AG

- (1) or any other person belonging to the same group with that person (as part of a consortium) within the past twelve months, acquired the financial instruments of the analysed company,
- (2) or any other person belonging to the same group with that person has entered into an agreement on the production of the research report with the analysed company,
- (3) has, within the past twelve months, been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement,
- (4) holds a) 5% or more of the share capital of the analysed company, or b) the analysed company holds 5% or more of the share capital of Hauck & Aufhäuser Privatbankiers AG or its affiliate(s).
- (5) holds a net long (a) or a net short (b) position of 0.5% of the outstanding share capital of the analysed company or derivatives thereof,
- (6) or any other person belonging to the same group with that person is a market maker or liquidity provider in the financial instruments of the issuer.
- or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company or a significant conflict of interest with respect to the issuer,
- (8) The research report has been made available to the company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosure

DFV Deutsche Familienversicherung AG

# Historical target price and rating changes for DFV Deutsche Familienversicherung AG in the last 12 months

# Price and Rating History DFV Deutsche Familienversicherung AG as of 12/11/20

Initiation coverage



Company	Date	Analyst	Rating	Target price	Close
DFV Deutsche Familienversicherung AG	02.11.2020	Salis, Christian	Buy	EUR 30,00	EUR 18,50
	04.09.2020	Salis, Christian	Buy	EUR 30,00	EUR 22,37
	14.08.2020	Salis, Christian	Buy	EUR 30,00	EUR 22,07
	03.07.2020	Salis, Christian	Buy	EUR 30,00	EUR 25,60

30.06.2020	Salis, Christian	Buy	EUR 30,00	EUR 23,30
16.06.2020	Salis, Christian	Buy	EUR 25,00	EUR 18,00
15.05.2020	Salis, Christian	Buy	EUR 25,00	EUR 18,00
20.03.2020	Salis, Christian	Buy	EUR 25,00	EUR 17,26
13.01.2020	Salis, Christian	Buy	EUR 23,50	EUR 19,42
28.11.2019	Salis, Christian	Buy	EUR 22,00	EUR 13,40
18.11.2019	Salis, Christian	Buy	EUR 17,50	EUR 10,07

# Hauck & Aufhäuser distribution of ratings and in proportion to investment banking services

Buy	70.00 %	83.33 %
Sell	9.33 %	0.00 %
Hold	20.67 %	16.67 %

Date of publication creation: 13/11/2020 07:51 AM

Date of publication dissemination: 13/11/2020 08:30 AM

#### 1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by Hauck & Aufhäuser Privatbankiers AG, exclusively to selected recipients [in DE, GB, FR, CH, US, UK, Scandinavia, and Benelux or, in individual cases, also in other countries]. A distribution to private investors in the sense of the German Securities Trading Act (WpHG) is excluded. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of Hauck & Aufhäuser Privatbankiers AG. Reproduction of this document, in whole or in part, is not permitted without prior permission Hauck & Aufhäuser Privatbankiers AG. All rights reserved.

Under no circumstances shall Hauck & Aufhäuser Privatbankiers AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

### 2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

#### 3. Organisational Requirements

Hauck & Aufhäuser Privatbankiers AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of Hauck & Aufhäuser Privatbankiers AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

#### 4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjustment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

Hauck & Aufhäuser Privatbankiers AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 10% within 12 months

Sell: Sustainable downside potential of more than 10% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

NB: The ratings of Hauck & Aufhäuser Privatbankiers AG are not based on a performance that is expected to be "relative" to the market.

The decision on the choice of the financial instruments analysed in this document was solely made by Hauck & Aufhäuser Privatbankiers AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of Hauck & Aufhäuser Privatbankiers AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

#### 5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. Hauck & Aufhäuser Privatbankiers AG has checked the information for plausibility but not for accuracy or completeness.

# 6. Competent Supervisory Authority

Hauck & Aufhäuser Privatbankiers AG are under supervision of the BaFin – German Federal Financial Supervisory Authority Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

This document is distributed in the UK under a MiFID EEA branch passport and in compliance with the applicable FCA requirements.

## 7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany. The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state.

#### 8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: https://www.hauck-aufhaeuser.com/en/investment-banking/equities#institutionalresearch

# Disclosures for U.S. persons only

This research report is a product of HAUCK & AUFHÄUSER PRIVATBANKIERS AG, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by HAUCK & AUFHÄUSER PRIVATBANKIERS AG, only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, HAUCK & AUFHÄUSER PRIVATBANKIERS AG, has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

# Contacts: Hauck & Aufhäuser Privatbankiers AG

#### Hauck & Aufhäuser Research

Hauck & Aufhäuser Privatbankiers AG Mittelweg 16/17 20148 Hamburg Germany

Tel.: +49 (0) 40 414 3885 91 Fax: +49 (0) 40 414 3885 71 Email: research@ha-ib.de www.ha-research.de

#### Tim Wunderlich, CFA

Head of Transactional Research Tel.: +49 40 414 3885 81 E-Mail: tim.wunderlich@ha-ib.de

#### Aliaksandr Halitsa

Analyst

Tel.: +49 40 414 3885 83 E-Mail: aliaksandr.halitsa@ha-ib.de

#### **Christian Salis**

Analyst

Tel.: +49 40 414 3885 96 E-Mail: christian.salis@ha-ib.de

#### Frederik Jarchow

Analyst

Tel: +49 40 414 3885 76 E-Mail: frederik.jarchow@ha-ib.de

#### **Henning Breiter**

Head of Research Tel.: +49 40 414 3885 73 E-Mail: henning.breiter@ha-ib.de

#### Alina Köhler

Analyst

Tel.: +49 40 450 6342 3095 E-Mail: alina.koehler@ha-ib.de

#### Christian Sandherr

Analyst

Tel.: +49 40 414 3885 79 E-Mail: christian.sandherr@ha-ib.de

#### Julius Stinauer

Analyst

Tel.: +49 40 414 3885 84 E-Mail: julius.stinauer@ha-ib.de

#### Marie-Thérèse Grübner

Head of Corporate Brokerage Tel.: +49 40 450 6342 3097

E-Mail: marie-therese.gruebner@ha-ib.de

#### **Christian Glowa**

Analyst

Tel.: +49 40 414 3885 95 E-Mail: christian.glowa@ha-ib.de

#### Frederik Bitter

Analyst Tel.: +49 40 450 6342 3091 E-Mail: frederik.bitter@ha-ib.de

#### Simon Bentlage

Analyst

Tel.: +49 40 450 6342 3096 E-Mail: simon.bentlage@ha-ib.de

## Hauck & Aufhäuser Sales

#### Alexander Lachmann

**Equity Sales** 

Tel.: +41 43 497 30 23

E-Mail: alexander.lachmann@ha-ib.de

# Christian Schwenkenbecher

**Equity Sales** 

Tel.: +44 203 9473 246

E-Mail: christian.schwenkenbecher@ha-ib.de

# Carlos Becke

**Equity Sales** 

Tel.: +44 203 9473 245 E-Mail: carlos.becke@ha-ib.de

## Christian Bybjerg

**Equity Sales** Tel.: +49 414 3885 74

E-Mail: christian.bybjerg@ha-ib.de

# Markus Scharhag

**Equity Sales** 

Tel.: +49 89 23 93 2813

E-Mail: markus.scharhag@ha-ib.de

#### **Hugues Madelin**

**Equity Sales** 

Tel.: +33 1 78 41 40 62 E-Mail: hugues.madelin@ha-ib.de

#### Vincent Bischoff

**Equity Sales** 

Tel.: +49 40 414 3885 88

E-Mail: vincent.bischoff@ha-ib.de

#### Imogen Voorspuy

**Equity Junior Sales** Tel: +44 203 9473 244

E-Mail: imogen.voorspuy@ha-ib.de

# Hauck & Aufhäuser Sales Trading

Hauck & Aufhäuser Privatbankiers AG Mittelweg 16/17 20148 Hamburg Germany

Tel.: +49 40 414 3885 78 Fax: +49 40 414 3885 71 Email: info@hauck-aufhaeuser.com www.hauck-aufhaeuser.com

# Christian von Schuler

Trading Tel.: +49 40 414 3885 77

E.Mail: christian.schuler@hauck-aufhaeuser.com

Trading Tel.: +49 40 414 3885 98

E.Mail: fin.schaffer@hauck-aufhaeuser.com

#### Kathleen Jonas

Middle-Office

Tel.: +49 40 414 3885 97

E.Mail: kathleen.jonas@hauck-aufhaeuser.com

# Fin Schaffer

#### Carolin Heidrich

Middle-Office

Tel.: +49 176 10 59 41 52

E-Mail: carolin.heidrich@hauck-aufhaeuser.com